We further found that the inhibition of prostate tumour growth may be attributable to the ability of miR-105 to reduce CDK6 levels, which is also supported by our data using hairpin inhibitors whereby reduced miR-105 levels in PrEC resulted in increased Cdk6 expression and enhanced growth in those cells. The gene discussed is CDK6; the disease is prostate neoplasm.